{"id":76814,"date":"2026-08-31T13:53:48","date_gmt":"2026-08-31T05:53:48","guid":{"rendered":"https:\/\/flcube.com\/?p=76814"},"modified":"2026-08-31T13:53:49","modified_gmt":"2026-08-31T05:53:49","slug":"takeda-wins-fda-approval-for-mimrylo-first-in-class-hepcidin-mimetic-for-polycythemia-vera","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76814","title":{"rendered":"Takeda Wins FDA Approval for MIMRYLO, First\u2011in\u2011Class Hepcidin Mimetic for Polycythemia Vera"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Takeda Pharmaceutical Company Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/4502:TYO\">TYO: 4502<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/TAK:NYSE\">NYSE: TAK<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has approved the New Drug Application for <strong>MIMRYLO (rusfertide)<\/strong> for the treatment of erythrocytosis in adults with <strong>polycythemia vera (PV)<\/strong>, a rare blood cancer. The clearance marks the arrival of a first\u2011in\u2011class hepcidin mimetic that targets the underlying iron dysregulation driving red blood cell overproduction in PV.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Agency<\/td><td><strong>U.S. Food and Drug Administration (FDA)<\/strong><\/td><\/tr><tr><td>Approval Type<\/td><td>New Drug Application (NDA)<\/td><\/tr><tr><td>Product<\/td><td><strong>MIMRYLO (rusfertide)<\/strong><\/td><\/tr><tr><td>Indication<\/td><td>Erythrocytosis in adults with polycythemia vera (PV)<\/td><\/tr><tr><td>Date<\/td><td>28 Aug 2026<\/td><\/tr><tr><td>Next Steps<\/td><td>U.S. commercial launch preparations and continued global regulatory submissions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Rusfertide, a synthetic hepcidin mimetic peptide<\/li>\n\n\n\n<li><strong>Target:<\/strong> Systemic iron distribution and red blood cell overproduction<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Regulates iron availability to control hematocrit \u2014 the ratio of red blood cells to total blood volume \u2014 addressing a core pathology of PV<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First\u2011in\u2011class; designed to maintain hematocrit below 45%, the primary treatment goal in PV<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Developed as an alternative to chronic phlebotomy, the current mainstay of hematocrit control<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-phase-3-verify-study\" class=\"wp-block-heading\">Clinical Evidence \u2013 Phase 3 VERIFY Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td>Study Design<\/td><td>Global, randomized, Phase 3 VERIFY trial (NCT05210790)<\/td><\/tr><tr><td>Population<\/td><td>293 adults with polycythemia vera<\/td><\/tr><tr><td>Hematocrit Control<\/td><td>Met; superior response with MIMRYLO plus standard of care vs. placebo plus standard of care<\/td><\/tr><tr><td>Phlebotomy Burden<\/td><td>Reduced need for phlebotomy in the MIMRYLO arm<\/td><\/tr><tr><td>Symptom Benefit<\/td><td>Improvement in fatigue per PROMIS Fatigue Short Form 8a<\/td><\/tr><tr><td>Safety<\/td><td>Favorable safety profile demonstrated<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">MIMRYLO met all efficacy endpoints in the VERIFY study, with patients receiving the drug alongside current standard of care achieving higher response rates than those on placebo plus standard of care. The benefit extended beyond laboratory measures to clinically meaningful outcomes, including fewer phlebotomy procedures and improved fatigue \u2014 two persistent burdens for patients living with PV.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011Mover Position:<\/strong> MIMRYLO becomes the first hepcidin mimetic approved for PV erythrocytosis, establishing a new therapeutic class<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> PV patients often depend on repeated phlebotomy; a mechanism\u2011based alternative addresses a long\u2011standing gap in care<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Differentiated from JAK inhibitors, which target symptom and spleen control rather than hematocrit\u2011driving iron dysregulation<\/li>\n\n\n\n<li><strong>Strategic Significance:<\/strong> Strengthens Takeda&#8217;s hematology\u2011oncology portfolio in rare blood cancers and supports its U.S. specialty growth agenda<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief contains forward\u2011looking statements regarding product launch, regulatory submissions, and commercial expectations. Actual results may differ materially due to risks inherent in drug development, regulatory review, and market competition. Readers should not place undue reliance on such statements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":77519,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11,4908],"tags":[874,15,345,1141],"class_list":["post-76814","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","category-pic","tag-nyse-tak","tag-product-approvals","tag-takeda","tag-tyo-4502"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Takeda Wins FDA Approval for MIMRYLO, First\u2011in\u2011Class Hepcidin Mimetic for Polycythemia Vera - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for MIMRYLO (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a rare blood cancer. The clearance marks the arrival of a first\u2011in\u2011class hepcidin mimetic that targets the underlying iron dysregulation driving red blood cell overproduction in PV.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76814\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda Wins FDA Approval for MIMRYLO, First\u2011in\u2011Class Hepcidin Mimetic for Polycythemia Vera\" \/>\n<meta property=\"og:description\" content=\"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for MIMRYLO (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a rare blood cancer. The clearance marks the arrival of a first\u2011in\u2011class hepcidin mimetic that targets the underlying iron dysregulation driving red blood cell overproduction in PV.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76814\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-31T05:53:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-31T05:53:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76814#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76814\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Takeda Wins FDA Approval for MIMRYLO, First\u2011in\u2011Class Hepcidin Mimetic for Polycythemia Vera\",\"datePublished\":\"2026-08-31T05:53:48+00:00\",\"dateModified\":\"2026-08-31T05:53:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76814\"},\"wordCount\":443,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76814#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/3101.webp\",\"keywords\":[\"NYSE: TAK\",\"Product approvals\",\"Takeda\",\"TYO: 4502\"],\"articleSection\":[\"Company\",\"Drug\",\"PIC\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76814#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76814\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76814\",\"name\":\"Takeda Wins FDA Approval for MIMRYLO, First\u2011in\u2011Class Hepcidin Mimetic for Polycythemia Vera - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76814#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76814#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/3101.webp\",\"datePublished\":\"2026-08-31T05:53:48+00:00\",\"dateModified\":\"2026-08-31T05:53:49+00:00\",\"description\":\"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for MIMRYLO (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a rare blood cancer. The clearance marks the arrival of a first\u2011in\u2011class hepcidin mimetic that targets the underlying iron dysregulation driving red blood cell overproduction in PV.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76814#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76814\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76814#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/3101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/3101.webp\",\"width\":1080,\"height\":608,\"caption\":\"Takeda Wins FDA Approval for MIMRYLO, First\u2011in\u2011Class Hepcidin Mimetic for Polycythemia Vera\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76814#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Takeda Wins FDA Approval for MIMRYLO, First\u2011in\u2011Class Hepcidin Mimetic for Polycythemia Vera\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Takeda Wins FDA Approval for MIMRYLO, First\u2011in\u2011Class Hepcidin Mimetic for Polycythemia Vera - Insight, China&#039;s Pharmaceutical Industry","description":"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for MIMRYLO (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a rare blood cancer. The clearance marks the arrival of a first\u2011in\u2011class hepcidin mimetic that targets the underlying iron dysregulation driving red blood cell overproduction in PV.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76814","og_locale":"en_US","og_type":"article","og_title":"Takeda Wins FDA Approval for MIMRYLO, First\u2011in\u2011Class Hepcidin Mimetic for Polycythemia Vera","og_description":"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for MIMRYLO (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a rare blood cancer. The clearance marks the arrival of a first\u2011in\u2011class hepcidin mimetic that targets the underlying iron dysregulation driving red blood cell overproduction in PV.","og_url":"https:\/\/flcube.com\/?p=76814","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-31T05:53:48+00:00","article_modified_time":"2026-08-31T05:53:49+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76814#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76814"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Takeda Wins FDA Approval for MIMRYLO, First\u2011in\u2011Class Hepcidin Mimetic for Polycythemia Vera","datePublished":"2026-08-31T05:53:48+00:00","dateModified":"2026-08-31T05:53:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76814"},"wordCount":443,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=76814#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3101.webp","keywords":["NYSE: TAK","Product approvals","Takeda","TYO: 4502"],"articleSection":["Company","Drug","PIC"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76814#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76814","url":"https:\/\/flcube.com\/?p=76814","name":"Takeda Wins FDA Approval for MIMRYLO, First\u2011in\u2011Class Hepcidin Mimetic for Polycythemia Vera - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=76814#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=76814#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3101.webp","datePublished":"2026-08-31T05:53:48+00:00","dateModified":"2026-08-31T05:53:49+00:00","description":"Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for MIMRYLO (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a rare blood cancer. The clearance marks the arrival of a first\u2011in\u2011class hepcidin mimetic that targets the underlying iron dysregulation driving red blood cell overproduction in PV.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76814#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76814"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=76814#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3101.webp","width":1080,"height":608,"caption":"Takeda Wins FDA Approval for MIMRYLO, First\u2011in\u2011Class Hepcidin Mimetic for Polycythemia Vera"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76814#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Takeda Wins FDA Approval for MIMRYLO, First\u2011in\u2011Class Hepcidin Mimetic for Polycythemia Vera"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3101.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76814"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76814\/revisions"}],"predecessor-version":[{"id":77520,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76814\/revisions\/77520"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/77519"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76814"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76814"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}